[go: up one dir, main page]

WO2009106748A3 - Dérivés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique - Google Patents

Dérivés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique Download PDF

Info

Publication number
WO2009106748A3
WO2009106748A3 PCT/FR2008/001833 FR2008001833W WO2009106748A3 WO 2009106748 A3 WO2009106748 A3 WO 2009106748A3 FR 2008001833 W FR2008001833 W FR 2008001833W WO 2009106748 A3 WO2009106748 A3 WO 2009106748A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
alkoxy
nrarb
optionally substituted
Prior art date
Application number
PCT/FR2008/001833
Other languages
English (en)
Other versions
WO2009106748A2 (fr
Inventor
Jean-François Peyronel
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2010541082A priority Critical patent/JP2011508758A/ja
Priority to BRPI0821674-6A priority patent/BRPI0821674A2/pt
Priority to CN200880123840XA priority patent/CN101910176A/zh
Priority to AT08872826T priority patent/ATE524468T1/de
Priority to EA201070816A priority patent/EA201070816A1/ru
Priority to AU2008351926A priority patent/AU2008351926A1/en
Priority to MX2010007348A priority patent/MX2010007348A/es
Priority to CA2710943A priority patent/CA2710943A1/fr
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to EP08872826A priority patent/EP2225241B1/fr
Publication of WO2009106748A2 publication Critical patent/WO2009106748A2/fr
Publication of WO2009106748A3 publication Critical patent/WO2009106748A3/fr
Priority to IL206668A priority patent/IL206668A0/en
Priority to US12/828,369 priority patent/US20100317685A1/en
Priority to ZA2010/04641A priority patent/ZA201004641B/en
Priority to MA33058A priority patent/MA32060B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composés de formule (I) dans laquelle: X représente un groupe phényle substitué; R1 représente un atome d'hydrogène, un halogène, un groupe (C1-C6)alcoxy, un groupe (C1-C6)alkyle, un groupe NRaRb; R2 représente un atome d'hydrogène, un groupe (C1-C6)alkyle éventuellement substitué,un groupe (C1-C6)alcoxy éventuellement substitué, un groupe (C2-C6)alcényle, un groupe (C2- C6)alcynyle, un groupe -CO-R5, un groupe -CO-NR6R7, un groupe -CO-O-R8, un groupe - NR9-CO-R10, un groupe -NR11R12, un groupe -N=CH-NRaRb, un atome d'halogène,un groupe cyano, nitro, hydroxyiminoalkyle, alcoxyiminoalkyle,un groupe (C1-C6)alkylthio, un groupe (C1-C6)alkylsulfinyle, un groupe (C1-C6)alkylsulfonyle, un groupe (((C1- C6)alkyl)3)silyléthynyle, un groupe -SO2-NR9R10, un groupe phényle éventuellement substitué par un ou plusieurs groupes choisis indépendamment les uns des autres parmi les atomes ou groupes suivants : halogène, (C1-C6)alcoxy, cyano, NRaRb, -CO-R5, -CO- NR6R7, -CO-O-R8, un groupe (C1-C6)alkyle éventuellement substitué par un ou plusieurs hydroxy ou NRaRb, R3 représente un atome d'hydrogène, un groupe (C1-C6)alkyle, un groupe (C1-C6)alcoxy ou un atome d'halogène, R4 représente un atome d'hydrogène, un groupe (C1-C4)alkyle, un groupe (C1-C4)alcoxy ou un atome de fluor, à l'état de base ou de sel d'addition à un acide. Utilisation en thérapeutique.
PCT/FR2008/001833 2008-01-02 2008-12-31 Dérivés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique WO2009106748A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MX2010007348A MX2010007348A (es) 2008-01-02 2008-12-31 Derivados de n-fenil-imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion terapeutica.
CN200880123840XA CN101910176A (zh) 2008-01-02 2008-12-31 N-苯基咪唑并[1，2-a]吡啶-2-甲酰胺衍生物，它们的制备和它们的治疗应用
AT08872826T ATE524468T1 (de) 2008-01-02 2008-12-31 Derivate aus n-phenyl-imidazo-(1,2-a)-pyridin-2- carboxamiden, ihre herstellung sowie ihre therapeutische anwendung
EA201070816A EA201070816A1 (ru) 2008-01-02 2008-12-31 Производные n-фенилимидазо[1,2-a]пиридин-2-карбоксамидов, их получение и их применение в терапии
AU2008351926A AU2008351926A1 (en) 2008-01-02 2008-12-31 Derivatives of N-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof
CA2710943A CA2710943A1 (fr) 2008-01-02 2008-12-31 Derives de n-phenyl-imidazo[1,2-.alpha.]pyridine-2-carboxamides, leur preparation et leur application en therapeutique
EP08872826A EP2225241B1 (fr) 2008-01-02 2008-12-31 Dérivés de N-phényl-imidazo-(1,2-A)-pyridine2-carboxamides, leur préparation et leur application en thérapeutique
JP2010541082A JP2011508758A (ja) 2008-01-02 2008-12-31 Ｎ−フェニルイミダゾ［１，２−α］ピリジン−２−カルボキサミド誘導体、これらの調製およびこれらの治療用途
BRPI0821674-6A BRPI0821674A2 (pt) 2008-01-02 2008-12-31 Derivados de n-fenil-imidazo[1,2-a] piridina-2- carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
IL206668A IL206668A0 (en) 2008-01-02 2010-06-28 N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-
US12/828,369 US20100317685A1 (en) 2008-01-02 2010-07-01 N-PHENYL-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
ZA2010/04641A ZA201004641B (en) 2008-01-02 2010-07-01 Derivatives of n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides,preparation thereof and therapeutic application thereof
MA33058A MA32060B1 (fr) 2008-01-02 2010-08-02 Dérivés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0800002A FR2925900B1 (fr) 2008-01-02 2008-01-02 DERIVES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR0800002 2008-01-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/828,369 Continuation US20100317685A1 (en) 2008-01-02 2010-07-01 N-PHENYL-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Publications (2)

Publication Number Publication Date
WO2009106748A2 WO2009106748A2 (fr) 2009-09-03
WO2009106748A3 true WO2009106748A3 (fr) 2009-12-30

Family

ID=39691313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/001833 WO2009106748A2 (fr) 2008-01-02 2008-12-31 Dérivés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique

Country Status (21)

Country Link
US (1) US20100317685A1 (fr)
EP (1) EP2225241B1 (fr)
JP (1) JP2011508758A (fr)
KR (1) KR20100099245A (fr)
CN (1) CN101910176A (fr)
AR (1) AR070071A1 (fr)
AT (1) ATE524468T1 (fr)
AU (1) AU2008351926A1 (fr)
BR (1) BRPI0821674A2 (fr)
CA (1) CA2710943A1 (fr)
CL (1) CL2008003926A1 (fr)
CO (1) CO6321243A2 (fr)
EA (1) EA201070816A1 (fr)
FR (1) FR2925900B1 (fr)
IL (1) IL206668A0 (fr)
MA (1) MA32060B1 (fr)
MX (1) MX2010007348A (fr)
TW (1) TW200942539A (fr)
UY (1) UY31586A1 (fr)
WO (1) WO2009106748A2 (fr)
ZA (1) ZA201004641B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903108B1 (fr) * 2006-07-03 2008-08-29 Sanofi Aventis Sa Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique.
FR2925906B1 (fr) * 2008-01-02 2010-08-20 Sanofi Aventis COMPOSES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638161A1 (fr) * 1988-10-24 1990-04-27 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US20050261315A1 (en) * 2003-11-13 2005-11-24 Ambit Biosciences Corporation Amide derivatives as kinase modulators
WO2006067446A1 (fr) * 2004-12-22 2006-06-29 Astrazeneca Ab Dérivés de pyridinecarboxamide employés en tant qu'agents anticancéreux
WO2008003856A1 (fr) * 2006-07-03 2008-01-10 Sanofi-Aventis Dérivés d'imidazo[1,2-a]pyridine-2-carboxamides leur préparation et leur application en thérapeutique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903108B1 (fr) * 2006-07-03 2008-08-29 Sanofi Aventis Sa Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique.
FR2925906B1 (fr) * 2008-01-02 2010-08-20 Sanofi Aventis COMPOSES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638161A1 (fr) * 1988-10-24 1990-04-27 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US20050261315A1 (en) * 2003-11-13 2005-11-24 Ambit Biosciences Corporation Amide derivatives as kinase modulators
WO2006067446A1 (fr) * 2004-12-22 2006-06-29 Astrazeneca Ab Dérivés de pyridinecarboxamide employés en tant qu'agents anticancéreux
WO2008003856A1 (fr) * 2006-07-03 2008-01-10 Sanofi-Aventis Dérivés d'imidazo[1,2-a]pyridine-2-carboxamides leur préparation et leur application en thérapeutique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] CAS; 1 March 2007 (2007-03-01), XP002493975, retrieved from STN Database accession no. 924038-88-0 (RN) *
DATABASE REGISTRY [online] CAS; 1 March 2007 (2007-03-01), XP002493976, retrieved from STN Database accession no. 924031-00-5 (RN) *
DATABASE REGISTRY [online] CAS; 1 March 2007 (2007-03-01), XP002493977, retrieved from STN Database accession no. 924102-15-8 (RN) *
DATABASE REGISTRY [online] CAS; 1 March 2007 (2007-03-01), XP002493978, retrieved from STN Database accession no. 924040-86-8 (RN) *
DATABASE REGISTRY [online] CAS; 28 August 2001 (2001-08-28), XP002493979, retrieved from STN Database accession no. 353258-70-5 (RN) *
DATABASE REGISTRY [online] CAS; 28 August 2001 (2001-08-28), XP002493980, retrieved from STN Database accession no. 353258-68-1 (RN) *

Also Published As

Publication number Publication date
CL2008003926A1 (es) 2010-02-12
US20100317685A1 (en) 2010-12-16
EP2225241B1 (fr) 2011-09-14
JP2011508758A (ja) 2011-03-17
ATE524468T1 (de) 2011-09-15
BRPI0821674A2 (pt) 2015-06-16
TW200942539A (en) 2009-10-16
IL206668A0 (en) 2010-12-30
EA201070816A1 (ru) 2010-12-30
AR070071A1 (es) 2010-03-10
MA32060B1 (fr) 2011-02-01
FR2925900B1 (fr) 2011-03-04
UY31586A1 (es) 2009-08-03
CA2710943A1 (fr) 2009-09-03
MX2010007348A (es) 2010-08-18
KR20100099245A (ko) 2010-09-10
WO2009106748A2 (fr) 2009-09-03
ZA201004641B (en) 2011-09-28
EP2225241A2 (fr) 2010-09-08
AU2008351926A1 (en) 2009-09-03
CN101910176A (zh) 2010-12-08
CO6321243A2 (es) 2011-09-20
FR2925900A1 (fr) 2009-07-03

Similar Documents

Publication Publication Date Title
MX358389B (es) Pesticidas mesoionicos de pirido [1,2-a] pirimidina.
EP1857457A3 (fr) Dérivé de benzimidazole et son utilisation comme antagoniste du récepteur AII
WO2008111441A1 (fr) Composition pharmaceutique
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
NO20064133L (no) 5,6-dialkyl-7-amino-triazolpyrimidiner, fremgangsmate for fremstilling- av dem, deres anvendelse for a bekjempe skadelig sopp, og midler som inneholder disse forbindelsene
MX2010008101A (es) Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un silanilo, su preparacion y su aplicacion en terapeutica.
WO2008108378A3 (fr) Dérivé bicyclique d'oxomorpholine
WO2009118473A3 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
AU2010326429B2 (en) Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor NOT modulators
WO2008006625A3 (fr) Dérivés de l'urée et des diamines apparentées, procédés pour leur préparation, et leur utilisation
WO2010010288A3 (fr) Derives de carbamates d' alkylthiazoles, leur preparation et leur utilisation comme inhbiteurs de l'enzyme faah
WO2008128009A3 (fr) Aminopyrimidines utilisees en tant qu'inhibiteurs de kinases
WO2009007536A8 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
WO2008003854A3 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
WO2006133928A3 (fr) Utilisation de phenylsemicarbazones pour le traitement des semences
WO2009106749A3 (fr) Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
WO2008142550A8 (fr) Dérivés spirocycliques
RU2012150795A (ru) Композиция для борьбы с заболеваниями растений и ее применение описание
WO2009106748A3 (fr) Dérivés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
WO2009106750A3 (fr) Dérivés 6-heterocyclique-imidazo[1,2-a]pyrroine-2-carboxamides, leur préparation et leur application en thérapeutique
WO2009115651A3 (fr) Composés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
MX2009006266A (es) Procedimientos de preparacion de 3-(4-(2,4-difluorobenciloxi)-3-br omo-6-metil-2-oxopiridin-1 (2h)-il)-n,4-dimetilbenzamida.
WO2009129259A3 (fr) Polymorphes de 5-(3-(éthylsulfonyl)phényl)-3,8-diméthyl-n-(1-méthylpipéridin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide et procédés d'utilisation associés
WO2009106752A3 (fr) Derives de 2-heteroaroyl-imidazol[1,2-a]pyridine, leur preparation et leur application en therapeutique
MX2011011246A (es) Derivados de 1-h-pirazolo [4,3-c] isoquinoleinas, su preparacion y su uso en terapeutica.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880123840.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08872826

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008872826

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2328/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 586471

Country of ref document: NZ

Ref document number: 2710943

Country of ref document: CA

Ref document number: 12010501498

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008351926

Country of ref document: AU

Ref document number: DZP2010000392

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20107014641

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010541082

Country of ref document: JP

Ref document number: MX/A/2010/007348

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 10080881

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008351926

Country of ref document: AU

Date of ref document: 20081231

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010003072

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 201070816

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0821674

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100630